References
- Pollmann R, Schmidt T, Eming R, et al. Pemphigus: a comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches. Clin Rev Allergy Immunol. 2018;54(1):1–25.
- Hebert V, Joly P. Rituximab in pemphigus. Immunotherapy. 2018;10(1):27–37.
- Alaibac M. Ultra-low dosage regimen of rituximab in autoimmune blistering skin conditions. Front Immunol. 2018;9:810.
- Didona D, Maglie R, Eming R, et al. Pemphigus: current and future therapeutic strategies. Front Immunol. 2019;10:1418.
- Abulayha A, Bredan A, El Enshasy H, et al. Rituximab: modes of action, remaining dispute and future perspective. Future Oncol. 2014;10:2481–2492.
- Huang A, Madan RK, Levitt J. Future therapies for pemphigus vulgaris: rituximab and beyond. J Am Acad Dermatol. 2016;74(4):746–753.
- Eming R, Nagel A, Wolff-Franke S, et al. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol. 2008;128:2850–2858.
- Arin MJ, Engert A, Krieg T, et al. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol. 2005;153(3):620–625.
- Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol. 2004;51(5):817–819.
- Cianchini G, Lupi F, Masini C, et al. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol. 2012;67(4):617–622.
- Leshem YA, Hodak E, David M, et al. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. J Am Acad Dermatol. 2013;68(3):404–411.
- Horváth B, Huizinga J, Pas HH, et al. Low-dose rituximab is effective in pemphigus. Br J Dermatol. 2012;166(2):405–412.
- Khopkar US, Chadha AA, Nitya MSN, et al. Follow-up data of rituximab as adjuvant therapy in pemphigus. Indian J Dermatol. 2017;62(6):671–673.
- Gupta J, Raval RC, Shah AN, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venereol Leprol. 2017;83(3):317–325.
- Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment-guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2015;29(3):405–414.
- Wang HH, Liu CW, Li YC, et al. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015;95(8):928–932.
- Schoergenhofer C, Schwameis M, Firbas C, et al. Single, very low rituximab doses in healthy volunteers – a pilot and a randomized trial: implications for dosing and biosimilarity testing. Sci Rep. 2018;8(1):124.
- Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357:545–552.
- Muller R, Hunzelmann N, Baur V, et al. Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris. Dermatol Res Pract. 2010;2010:321950.
- Lunardon L, Tsai KJ, Propert KJ, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012;148:1031–1036.
- Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet Lond Engl. 2017;389:2031–2040.
- Murrell DF, Pena S, Joly P, et al. Diagnosis and management of pemphigus: recommendations by an international panel of experts. J Am Acad Dermatol. 2018;2:21.
- Ferranti M, Tadiotto Cicogna G, Sattin A, et al. Citrobacter freundii sepsis in an immunosuppressed patient with pemphigus vulgaris. BMJ Case Rep. 2018;11(1):e227091.
- Vinay K, Cazzaniga S, Amber KT, et al. Rituximab as first-line adjuvant therapy for pemphigus: retrospective analysis of long term outcomes at a single center. J Am Acad Dermatol. 2018;78:806–808.
- Belloni-Fortina A, Faggion D, Pigozzi B, et al. Detection of autoantibodies against recombinant desmoglein 1 and 3 molecules in patients with pemphigus vulgaris: correlation with disease extent at the time of diagnosis and during follow-up. Clin Dev Immunol. 2009;2009:187864.
- Russo I, De Siena FP, Saponeri A, et al. Evaluation of anti-desmoglein-1 and anti-desmoglein-3 autoantibody titers in pemphigus patients at the time of the initial diagnosis and after clinical remission. Medicine (Baltimore). 2017;96(46):e8801.